Novochizol has published new preclinical results in Pharmaceutics on an intranasal vaccine approach against highly pathogenic avian influenza A/H5, formulated with its chitosan-derived delivery platform.
On June 16, BioArk Tech Park in Monthey had the pleasure of welcoming around 120 representatives from the Canton of Valais for a discovery afternoon dedicated to innovation, education, and life sciences.
Discovering BioArk Ecosystem: OSP and SHE Visit Monthey Tech Park Read More »
Ninsun Biotech will present NinStem Lung™, its diagnostic test in development for predicting response to immunotherapy in non-small cell lung cancer, at the IFODS ONCO STARTUP SUMMIT in Paris on 18 June 2026.
Ninsun Biotech to present an NSCLC immunotherapy response biomarker at IFODS Read More »
Bioscibex, a startup hosted at BioArk TechPark in Monthey, has been awarded the 2026 Prix Créateurs BCVS. The recognition highlights SW1NGO, an innovative bioreactor that simplifies cell therapy production, reduces costs and contamination risks, and supports the development of treatments for cancer and autoimmune diseases.
BioArk startup Bioscibex wins Prix Créateurs BCVS 2026 Read More »
Siegfried Evionnaz operates as a drug-substance development and manufacturing site within the Siegfried Group
Siegfried Evionnaz: API development and industrial manufacturing Read More »
An INSIDE event hosted by TRB Chemedica brought together more than 30 members of the Swiss Health Valley ecosystem for an immersive evening exploring biopharmaceutical innovation, therapeutic expertise and industrial excellence in Switzerland.
INSIDE TRB Chemedica: when innovation meets patient-centric vision Read More »
Compagnie industrielle de Monthey SA (CIMO) operates as a central infrastructure and industrial services provider for the Monthey chemical site
CIMO: Integrated industrial services in Monthey Read More »
On 4 and 5 May 2026, Basel once again became a meeting point for the international biotech community during Swiss Biotech Day. This year’s edition gathered more than 3,500 participants, over 130 exhibitors and 25 international delegations. Valais was represented by Economic Promotion Valais, BioArk and HES-SO Valais/Wallis. For the Valais delegation, the objective was
The Swiss Biotech Report 2026 highlights Switzerland’s strong biotech performance and the growing role of Valais in bioproduction, applied research and life sciences innovation.
The third edition of Venture Technology Connect will take place on November 4, 2026, in Le Châble (Verbier). The event brings together startups and private investors in a setting designed to facilitate direct exchanges and structured discussions. A format focused on investor-startup interactions The program combines several formats aimed at fostering connections: keynote presentations pre-arranged
Venture Technology Connect returns on November 4 in Verbier Read More »
